Interleukin 6 (IL6) as a potential interplaying factor between obesity and COVID-19 outcome

Obesity is associated with chronic low-grade inflammation and severe COVID-19. Interleukin 6 (IL6) is a key mediator of cytokine storm hyperinflammation. However, it is unknown if IL6 is involved in the link between obesity and COVID-19 outcomes. Observational retrospective research was conducted be...

Full description

Saved in:
Bibliographic Details
Published in:Informatics in medicine unlocked 2024, Vol.45, p.101455, Article 101455
Main Authors: Hafez, Wael, Nasa, Prashant, Rashid, Asrar, Saleh, Husam, Abuelsaoud, Hesham Mohamed, Abdelshakour, Mahmoud, Nashef, Zainab, Abazid, Reem Rizk, Ahmed, Azza Bakr, Ahmed, Shougyat, Gador, Muneir, Faheem, Youmna, John, Steffi, Mohamed, Ahmed Ali, Abdoh, Aya
Format: Article
Language:English
Subjects:
Body mass index
COVID-19
Interleukin 6
Mortality
Obesity
Public health
Severity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity is associated with chronic low-grade inflammation and severe COVID-19. Interleukin 6 (IL6) is a key mediator of cytokine storm hyperinflammation. However, it is unknown if IL6 is involved in the link between obesity and COVID-19 outcomes. Observational retrospective research was conducted between September 8, 2020, and September 30, 2021. BMI-varying COVID-19 patient data were collected. Demographic, clinical, radiographic, and laboratory variables were assessed. COVID-19 outcomes were examined in relation to body mass index () and IL6 levels. More than half of the participants (60.4 %) were elderly individuals. A quarter of the study population was non-obese, and 6.6 % had 3rd-degree obesity. Individuals with normal weight and class I obesity had higher IL-6 levels (70.1 % and 75.6 %, respectively). Severe cases were more likely to have higher IL-6 levels than non-severe cases (p 
ISSN:2352-9148
2352-9148
DOI:10.1016/j.imu.2024.101455